Insider Selling: Privia Health Group, Inc. (NASDAQ:PRVA) EVP Sells 10,000 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVAGet Rating) EVP Thomas Bartrum sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $29.24, for a total value of $292,400.00. Following the transaction, the executive vice president now directly owns 91,355 shares in the company, valued at approximately $2,671,220.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Bartrum also recently made the following trade(s):

  • On Monday, June 6th, Thomas Bartrum sold 10,000 shares of Privia Health Group stock. The shares were sold at an average price of $25.01, for a total value of $250,100.00.
  • On Wednesday, April 20th, Thomas Bartrum sold 10,000 shares of Privia Health Group stock. The shares were sold at an average price of $27.93, for a total value of $279,300.00.
  • On Monday, March 28th, Thomas Bartrum sold 10,000 shares of Privia Health Group stock. The shares were sold at an average price of $25.09, for a total value of $250,900.00.

NASDAQ PRVA traded up $1.18 during trading hours on Thursday, hitting $29.76. 997,290 shares of the company’s stock were exchanged, compared to its average volume of 702,554. The business’s 50 day moving average is $24.68 and its 200-day moving average is $24.27. Privia Health Group, Inc. has a 12-month low of $17.99 and a 12-month high of $50.77. The firm has a market capitalization of $3.23 billion, a P/E ratio of -14.01 and a beta of 1.68. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.24 and a current ratio of 2.24.

Privia Health Group (NASDAQ:PRVAGet Rating) last released its earnings results on Tuesday, March 22nd. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.17. Privia Health Group had a negative return on equity of 47.87% and a negative net margin of 19.80%. The firm had revenue of $275.33 million for the quarter, compared to the consensus estimate of $226.06 million. As a group, equities research analysts anticipate that Privia Health Group, Inc. will post -0.14 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. purchased a new position in Privia Health Group during the fourth quarter worth about $25,000. First Horizon Advisors Inc. purchased a new position in Privia Health Group during the fourth quarter worth about $26,000. FourThought Financial LLC lifted its position in Privia Health Group by 77.2% during the first quarter. FourThought Financial LLC now owns 2,417 shares of the company’s stock worth $65,000 after buying an additional 1,053 shares during the period. US Bancorp DE lifted its position in Privia Health Group by 8.8% during the first quarter. US Bancorp DE now owns 13,923 shares of the company’s stock worth $372,000 after buying an additional 1,131 shares during the period. Finally, Blair William & Co. IL lifted its position in Privia Health Group by 9.2% during the first quarter. Blair William & Co. IL now owns 17,412 shares of the company’s stock worth $465,000 after buying an additional 1,463 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Several analysts have weighed in on PRVA shares. SVB Leerink upped their target price on Privia Health Group from $43.00 to $44.00 and gave the company an “outperform” rating in a report on Friday, March 25th. Guggenheim started coverage on Privia Health Group in a report on Tuesday, March 29th. They issued a “buy” rating and a $35.00 target price on the stock. Canaccord Genuity Group lowered their target price on Privia Health Group from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, March 24th. Canaccord Genuity Group reduced their price objective on Privia Health Group from $44.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, May 13th. Finally, BTIG Research started coverage on Privia Health Group in a research report on Thursday, April 28th. They issued a “buy” rating and a $35.00 price objective on the stock. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $39.08.

Privia Health Group Company Profile (Get Rating)

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

Featured Articles

Insider Buying and Selling by Quarter for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.